Potential and Emerging Treatment Options for Ebola Virus Disease

Annals of Pharmacotherapy

Volumn 49, Issue 2, 2015, Pages 196-206

  Bishop, Bryan M ^a,b  

^a St Rita's Medical Center   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

antivirals; Ebola; Ebola treatment; Ebola vaccine; Ebola virus

Indexed keywords

AMIODARONE; ANTIVIRUS AGENT; BRINCIDOFOVIR; CHIMPANZEE ADENOVIRUS SEROTYPE 3; CHLOROQUINE; CLOMIFENE; FAVIPIRAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; RECOMBINANT VESICULAR STOMATITIS VIRUS; RVSV EBOLA; TKM EBOLA; UNCLASSIFIED DRUG; ZMAPP; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD TRANSFUSION; DISEASE TRANSMISSION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTROLYTE DISTURBANCE; EPIDEMIC; EXPERIMENTAL THERAPY; FLUID RESUSCITATION; HUMAN; IMMUNOTHERAPY; INFECTIOUS COMPLICATION; MEDLINE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; SHOCK; VESICULOVIRUS; ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; POST-EXPOSURE PROPHYLAXIS; VIRAL VACCINES;

EID: 84920982449     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014561227     Document Type: Review

References (77)

1. Bray MClinical Virology. Richman DDWhitley RJHayden FG, ed. Washington, DC: ASM Press; 2002:875.
2. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections.N Engl J Med. 2014;371:1481-1495
3. Bray M.Pathogenesis of viral hemorrhagic fever.Curr Opin Immunol. 2005;17:399-403
4. World Health Organization. What we know about transmission of the Ebola virus among humans. http://www.who.int/media-centre/news/ebola/06-october-2014/en/. Accessed October 21, 2014.
5. Sagripanti JL,Rom AM,Holland LE.Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces.Arch Virol. 2010;155:2035-2039
6. Piercy TJ,Smither SJ,Steward JA,Eastaugh L,Lever MS.The survival of filovirusis in liquids, on solid substrates and in a dynamic aerosol.J Appl Microbiol. 2010;109:1531-1539
7. World Health Organization. Barriers to rapid containment of the Ebola outbreak. http://www.who.int/csr/disease/ebola/overview-august-2014/en/. Accessed October 21, 2014.
8. The Centers for Disease Control and Prevention. Ebola virus disease information for clinicians in U.S. healthcare settings. http://www.cdc.gov/vhf/ebola/hcp/clinician-information-us-healthcare-settings.html. Accessed October 21, 2014.
9. Bwaka MA,Bonnet M-J,Calain P, et al.Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients.J Infect Dis. 1999;179:S1-S7
10. The Centers for Disease Control and Prevention. Interim guidance for specimen collection, transport, testing, and submission for persons under investigation for Ebola virus disease in the United States. http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html. Accessed October 21, 2014.
11. Clinical Management of Patients With Viral Hemorrhagic Fever: A Pocket-Guide for the Frontline Health Worker. Geneva, Switzerland: WHO; 2014:
12. WHO Consultation on Potential Ebola Therapies and Vaccines: Background Document for Participants. Geneva, Switzerland: World Health Organization; 2014:
13. PollackA. Second drug is allowed for treatment of Ebola. http://www.nytimes.com/2014/08/08/health/second-experimental-drug-allowed-for-treating-ebola.html. Accessed October 21, 2014.
14. Pettitt J,Zeitlin L,Kim DH, et al.Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.Sci Transl Med. 2013;5:199ra113
15. Qiu X,Wong G,Audet J, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.Nature. 2014;514:47-53
16. McCarthy M.US signs contract with ZMapp maker to accelerate development of the Ebola drug.BMJ. 2014;349:g5488
17. Gulland A.First Ebola treatment is approved by WHO.BMJ. 2014;349:g5539
18. Mupapa K,Massamba M,Kibadi K, et al.Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients.J Infect Dis. 1999;179:S18-S23
19. Burnouf T,Emmanuel J,Mbanya D, et al.Ebola: a call from blood transfusion strategy in sub-Saharan Africa.Lancet. 2014;384:1347-1348
20. BesserR. Why Dr. Kent Brantly couldn’t donate blood to Thomas Eric Duncan. http://abcnews.go.com/Health/dr-kent-brantly-donate-blood-thomas-eric-duncan/story?id=26226388. Accessed October 21, 2014.
21. Sobarzo A,Ochayon DE,Lutwama JJ, et al.Persistent immune responses after Ebola virus infection.N Engl J Med. 2013;369:492-493
22. ChristensenJ. Ebola drugs are in the works. http://www.cnn.com/2014/10/06/health/ebola-drugs-in-the-works/. Access-ed November 1, 2014.
23. Chimerix Inc. Chimerix announces emergency investigational new drug applications for brincidofovir authorized by FDA for patients with Ebola virus disease. http://ir.chimerix.com/releasedetail.cfm?releaseid=874647. Accessed October 21, 2014.
24. Lanier R,Trost L,Tippin T, et al.Development of CMX001 for the treatment of poxvirus infections.Viruses. 2010;2:2740-2762
25. Chimerix. An open-label, multicenter study of the safety and anti-viral activity of brincidofovir (BCV, CMX001) for Ebola virus disease. http://www.clinicaltrials.gov/ct2/show/NCT0227-1347. Accessed November 10, 2014.
26. WileyF. The 3 drug classes for experimental Ebola treatment. http://www.pharmacytimes.com/contributor/frieda-wiley/2014/10/the-3-drug-classes-for-experimental-ebola-treatment. Acces-sed November 2, 2014.
27. CaplanA. New drug brincidofovir may be useful in treating Ebola: expert. http://www.nydailynews.com/life-style/health/new-drug-brincidofovir-treating-ebola-expert-article-1.19866-81. Accessed November 2, 2014.
28. Marty FM,Winston DJ,Rowley SD, et al.CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.N Engl J Med. 2013;369:1227-1236
29. Painter W,Robertson A,Trost LC,Godkin S,Lampert B,Painter G.First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.Antimicrob Agents Chemother. 2012;56:2726-2734
30. Sangawa H,Komeno T,Nishikawa H, et al.Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.Antimicrob Agents Chemother. 2013;57:5202-5208
31. Gowen BB,Smee DF,Wong MH, et al.Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.PLoS One. 2008;3:e3725
32. Gowen BB,Wong MH,Jung KH, et al.In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.Antimicrob Agents Chemother. 2007;51:3168-3176
33. Safronetz D,Falzarano D,Scott DP,Furuta Y,Feldmann H,Gowen BB.Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.Antimicrob Agents Chemother. 2013;57:4673-4680
34. Oestereich L,Ludtke A,Wurr S,Rieger T,Munoz-Fontela C,Gunther S.Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.Antiviral Res. 2014;105:17-21
35. Smither SJ,Eastaugh LS,Steward JA,Nelson M,Lenk RP,Lever MS.Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model.Antiviral Res. 2014;105:153-155
36. TrompizG. First French Ebola patient leaves hospital. http://www.reuters.com/article/2014/10/04/us-health-ebola-france-id-USKCN0HT0D720141004. Accessed October 21, 2014.
37. KoonsCMatsuyamaKLangrethR. Ebola drug from Japan may emerge among key candidates. http://www.bloomberg.com/news/2014-08-07/ebola-drug-from-japan-may-emerge-among-key-candidates.html. Accessed October 17, 2014.
38. McCarthy M.FDA allows second experimental drug to be tested in Ebola patients.BMJ. 2014;349:g5103
39. Geisbert TW,Lee ACH,Robbins M, et al.Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.Lancet. 2010;375:1896-1905
40. Iverson PL,Warren TK,Wells JB, et al.Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.Viruses. 2012;4:2806-2830
41. Xu W,Edwards MR,Borek DM, et al.Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.Cell Host Microbe. 2014;16:187-200
42. Heald AE,Iverson PL,Saoud JB, et al.Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies.Antimicrob Agents Chemother. 2014;58:6639-6647
43. Warren TK,Wells J,Panchal RG, et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.Nature. 2014;508:402-405
44. BeaubienJ. A Liberian doctor comes up with his own Ebola regimen. http://www.npr.org/blogs/goatsandsoda/2014/10/10/355164328/a-liberian-doctor-comes-up-with-his-own-ebola-re-gimen. Accessed November 2, 2014.
45. FauciASCollinsFS. NIH Ebola update: working toward treatments and vaccines. http://directorsblog.nih.gov/2014/10/14/nih-ebola-update-working-toward-treatments-and-vaccines/. Accessed November 2, 2014.
46. Madrid PB,Chopra S,Manger ID, et al.A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.PLoS One. 2013;8:e60579
47. De Lamballerie X,Boisson V,Reynier JC, et al.On chikungunya acute infection and chloroquine treatment.Vector Borne Zoonotic Dis. 2008;8:837-839
48. Tricou V,Minh NN,Van TP, et al.A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.PLoS Negl Trop Dis. 2010;4:e785
49. White JM,Schornberg KL.A new player in the puzzle of filovirus entry.Nat Rev Microbiol. 2012;10:317-322
50. Geisbert TW,Young HA,Jahrling PB, et al.Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.Am J Pathol. 2003;163:2371-2382
51. Johansen LM,Brannan JM,Delos SE, et al.FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Sci Transl Med. 2013;5:190ra79
52. Gehring G,Rohrmann K,Atenchong N, et al.The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.J Antimicrob Chemother. 2014;69:2123-2131
53. Patel JM,Snaith C,Thickett DR, et al.Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial).Crit Care. 2012;16:R231
54. Undas A,Brummel-Ziedins KE,Mann KG.Anticoagulant effects of statins and their clinical implications.Thromb Haemost. 2014;111:392-400
55. Fedson DS.A practical treatment for patients with Ebola virus disease.J Infect Dis. 2014;:
56. Wan YD,Sun TW,Kan QC,Guan FX,Zhang SG.Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies.Crit Care. 2014;18:R71
57. Pasin L,Landoni G,Castro ML, et al.The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials.PLoS One. 2013;8:e82775
58. Ou SY,Chu H,Chao PW, et al.Effect of the use of low and high potency statins and sepsis outcomes.Intensive Care Med. 2014;40:1509-1517
59. Martinez-Gutierrez M,Castellanos JE,Gallego-Gomez JC.Statins reduce dengue virus production via decreased virion assembly.Intervirology. 2011;54:202-216
60. Whitehorn J,Van Vinh Chao N,Truong NT, et al.Lovastatin for adult patients with dengue: protocol for a randomised controlled trial.Trials. 2012;13:203
61. Stanley DA,Honko AN,Asiedu C, et al.Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge.Nat Med. 2014;20:1126-1129
62. Geisbert TW,Geisbert JB,Leung A, et al.Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus.J Virol. 2009;83:7296-7304
63. Kanapathipillai R,Restrepo AM,Fast P, et al.Ebola vaccine: an urgent international priority.N Engl J Med. 2014;:
64. Jones SM,Feldmann H,Stroher U, et al.Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Nat Med. 2005;11:786-790
65. Qiu X,Fernando L,Alimonti JB, et al.Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses.PLoS One. 2009;4:e5547
66. Geisbert TW,Daddario-DiCaprio KM,Geisbert JM, et al.Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.Vaccine. 2008;26:6894-6900
67. Mullard A.Experimental Ebola drugs enter the limelight.Lancet. 2014;384:649
68. Feldmann H,Jones SM,Daddario-DiCaprio KM, et al.Effective post-exposure treatment of Ebola infection.PLoS Pathog. 2007;3:e2
69. Fowler RA,Fletcher T,Fischer WA, et al.Caring for critically ill patients with Ebola virus disease: perspectives from West Africa.Am J Respir Crit Care Med. 2014;190:733-737
70. Ribner BS.Treating patients with Ebola virus infections in the US: lessons learned.Paper presented at: IDWeek; Philadelphia, PA;.
71. Clark DV,Jahrling PB,Lawler JV.Clinical management of filovirus-infected patients.Viruses. 2012;4:1668-1686
72. Feldmann H,Geisbert TW.Ebola hemorrhagic fever.Lancet. 2011;377:849-862
73. Koo HL,Koo DC,Musher DM,DuPont HL.Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis.Clin Infect Dis. 2009;48:598-605
74. Infectious Diseases Society of America. IDSA Ebola guidance. http://www.idsociety.org/2014_ebola/. Accessed November 2, 2014.
75. Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of Medical Microbiology and Infectious Diseases Canada. Ebola clinical care guidelines: a guide for clinicians in Canada. http://www.healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/ebola/professionals-professionnels/index-eng.php. Accessed November 11, 2014.
76. Filovirus Haemorrhagic Fever Guideline. Barcelona, Spain: Médecins Sans Frontières; 2008:
77. Management of Hazard Group 4 Viral Haemorrhagic Fevers and Similar Human Infectious Diseases of High Consequence. London, UK: Advisory Committee on Dangerous Pathogens; 2014: